Henry Schein (HSIC), a leading player in the bio-tech market, has completed a substantial
$250 million investment by KKR. Concurrently, the firm is considered a top momentum stock for the long term and consistently ranks as a top value and growth stock, reflective of its significant growth since the last earnings report. Repeated Q1 earnings reports indicate
margin gains, along with flat revenue navigated by strategic shifts. Notably, HSIC's strong global sales growth comes amid several economic challenges. HSIC also marked its upcoming participation in multiple investor conferences.
KKR increased its stake in Henry Schein, leading to board changes and preliminary unaudited financial results. It received validation of net-zero science-based targets and restructured for growth with an expectation of strong performance for 2025. The company recently completed the acquisition of
Acentus, a major supplier of homecare medical products. As it continues its strategic investments, HSIC remains an attractive value and growth investment, however, challenges also persist. The question whether to retain HSIC stocks in their portfolio has also been raised repeatedly.
Henry Schein HSIC News Analytics from Wed, 25 Sep 2024 07:00:00 GMT to Thu, 10 Jul 2025 13:50:02 GMT -
Rating 7
- Innovation 6
- Information 8
- Rumor -8
